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Enhanced production of biologically active 
interleukin-la and interleukin-lfi by psoriatic 
epidermal cells ex vivo: evidence of increased 
cytosolic interleukin-lfi levels and facilitated 
interleukin-1 release 
The expression of interleukin (1L)-1 is altered in psoriatic lesions. However, lit- 
tle is known about the actual production of IL-la and IL-lP by psoriatic epider- 
mal cells (EC). We monitored IL-1 in the extracellular, the membrane and the 
intracellular compartment of freshly isolated EC from untreated lesional pso- 
riatic (PP) and normal healthy (NN) skin during non-stimulated short-term cul- 
tures, representing a psoriasis model ex vivo. Cytokines were measured using 
bioassays combined with neutralizing antibodies and enzyme-linked immuno- 
sorbent assay in parallel. PP EC released significantly increased amounts of bio- 
logically active IL-la and IL-lP in a ratio of 3 : 1, whereas NN EC only released 
IL-la. Also, the release of IL-6, but not of TNF-a, by PP EC was significantly 
increased. Membrane-associated IL-1 activity, analyzed using glutaraldehyde- 
fixed EC, was low and not unique to PP EC. The cytosol of PP EC contained sig- 
nificantly increased levels of immunoreactive IL-1P. Furthermore, PP EC dis- 
played loss of membrane integrity, as determined by trypan blue exclusion and 
release of cytosolic lactate dehydrogenase. This facilitated release of intracellu- 
lar IL-1. Depletion of CD45+ cells showed that intraepidermal leukocytes did 
not contribute to the production of IL-1. Our observations show that resident PP 
EC express enhanced IL-1 production ex vivo, which is due to an increased cyto- 
solic IL-1P content and facilitated IL-1 release. This study provides the first evi- 
dence that PP EC can produce bioactive IL-1p. 
1 Introduction 
Human epidermal IL-1 is safely stored in the cytosol of the 
keratinocyte and stimuli (e .g .  cell injury, T cell interaction) 
are required for its release [l]. Intracellularly stored IL-1 
consists of pro-IL-la and pro-IL-1P, which both lack a sig- 
nal peptide but differ in the way they are processed and 
modified after translation [2]. Pro-IL-la is fully biologi- 
cally active, whereas pro-IL-1fi has minimal biological 
activity [3]. Cultured normal human keratinocytes are 
unable enzymatically to cleave pro-IL-P efficiently to the 
active mature form [4]. This implies that in normal human 
epidermis, all IL-1 activity is due to IL-la [5]. 
The epidermal expression of IL-1 is altered in psoriasis. 
IL-la protein is reported to be decreased in cytosolic 
extracts of psoriatic skin (PP) specimens and aqueous 
extracts of the stratum corneum, resulting in a consider- 
able decrease of the total epidermal IL-1 activity [6-81. IL- 
la levels were low but not decreased in suction blister 
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fluids from PP skin [9]. In contrast to IL-la, cytosolic 
extracts of PP skin contained increased levels of a pro- 
cessed, but non-functional form of IL-16 [6, 71. IL-1fi 
levels were negligible in extracts of the stratum corneum 
and in blister fluids [8, 91 and its expression seemed con- 
fined to the plasma membrane and the intracellular com- 
partment of epidermal cells (EC) [lo, 111. The down- 
regulation of IL-la and up-regulation of IL-lP found with 
cytosolic skin extracts was not observed using immunohis- 
tochemistry [lo]. Conflicting reports also exist on the 
expression of the IL-1-related cytokines IL-6 and TNF-a in 
psoriatic epidermis [8, 12, 131. Taken together, available 
data are complex and inconsistent due to analysis of cyto- 
kines in different cellular compartments and at different 
levels of expression. To clarify the altered expression of 
epidermal cytokines in psoriasis, the focus of the present 
study was to characterize the actual production of IL-1, 
IL-6 and TNF-a by PP EC. 
We investigated the spontaneous release of these cytokines 
during short-term cultures of freshly isolated EC from 
untreated PP and normal healthy (NN) skin, using a 
defined low-calcium basal medium. We considered these 
cultures to be an ex vivo model which is less prone to in 
vitro artefacts than cell lines. To study the epidermal IL-1 
production in psoriasis, the extracellular, the membrane 
and the intracellular compartment of the same EC samples 
were analyzed for IL-1. Moreover, EC samples were 
assayed for several cytokines simultaneously and for differ- 
ent levels of protein expression in parallel. We tested for 
biologically active and immunoreactive IL-la, IL-lp, IL-6 
and TNF-a. 
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2 Materials and methods 2.6 Bioassays 
2.1 Patients and controls 
Thirty-five otherwise healthy patients (Outpatient Depart- 
ment of Dermatology, University Hospital Rotterdam- 
Dijkzigt) with plaque-type psoriasis were studied after 
informed consent. Patients remained untreated for at least 
3 weeks before entering the study. Thirty-five healthy 
volunteers without history or signs of skin disease, under- 
going abdominal or breast plastic surgery (Sint Franciscus 
Hospital, Rotterdam) served as controls. Skin samples 
were collected after approval of the institutional medical 
ethical committee (MEC 104.050/SPO/1990/30). 
2.2 EC suspensions 
Split-skin specimens from PP and NN skin of 10-15 cm2 
were obtained using a portable dermatome (Davol, Crans- 
ton, RI). Preparation of single EC suspensions was based 
on standard methods [14]. Cells were resuspended in a 
chemically defined keratinocyte basal medium (KBM/ 
unsupplemented MCDB 153, Clonetics, San Diego, CA). 
Cells were counted microscopically using phase-contrast 
illumination. Viability was determined by trypan blue 
exclusion. 
2.3 EC-conditioned media 
EC were seeded at 106 viable celldm1 in 2 ml KBM in 
25 cm2 vented culture flasks (Costar, Cambridge, MA). 
After culture for 24 h, the viability of the cells was checked 
and SN were collected by centrifugation, filter-sterilized, 
supplemented with 0.1 YO BSA and stored at - 80 "C. 
IL-1 activity was measured using a subline of the murine 
Tcell line D10.G4.1, designated DlO(N4)M (D10) (kindly 
provided by Dr. S. J. Hopkins, Manchester, GB) [16]. Fur- 
ther optimization of the assay at our laboratory resulted in 
enhanced reproducibility of the test [17]. IL-6 activity was 
measured using the murine hybridoma cell line B9 (kindly 
donated by Prof. Dr. L. A. Aarden, Amsterdam, The 
Netherlands) [ 181. Proliferation of the cytokine-dependent 
cell lines D10 and B9 was measured by [3H]dThd incor- 
poration. TNF-a activity was measured using the murine 
fibroblast cell line WEHI 164.13 (kindly provided by Dr. W. 
A. Buurman, Maastricht, The Netherlands) [19]. The MTT 
cytotoxicity assay [20] served as an indirect measurement of 
necrosis of WEHI cells. Recombinant human (Hu)IL-lP 
(UBI, Lake Placid, NY), rHuIL-6 (Prof. Dr. L. A. Aarden) 
and rHuTNF-a (UBI) served as positive controls in the 
D10, B9 and WEHI assays, respectively. Cytokine activities 
were corrected for background activity of the culture 
medium and expressed in U per 106 viable cells, with 1 U/ 
ml corresponding with the half-maximal response. 
Neutralization experiments using the D10 assay were 
performed with sheep-anti-rHuIL-la and/or IL-1P Ab 
(Glaxo, Geneva, Switzerland). After addition of the Ab to 
the optimally diluted samples and incubation for 45 min at 
37 "C and 5 YO C02 ,  the D10 cells were added. The anti-IL- 
la and IL-1P Ab, used at a titer of 15000, neutralized 
about 10 U/ml natural NN EC-derived IL-la and PBMC- 
derived IL-lP, respectively. Neutralization results are 
given as the percentage residual IL-1 activity and were cal- 
culated using the formula: 
YO residual IL-1 activity = 
cpm neutralized sample - cpm background 
cpm non-neutralized sample - cpm background 
x 100% 
2.4 Fixation of EC 
2.7 ELISA 
Freshly isolated EC or EC cultured for 24 h, were fixed 
with freshly prepared 0.08 YO glutaraldehyde (Merck, 
Schuchardt, FRG) in 0.1 M sodium cacodylate buffer 
pH 6.9 for 10 s at 4°C. Subsequently, cells were washed 
twice with Hepes-buffered RPMI 1640 containing 0.5 YO 
BSA. Next, cells were resuspended at 106/ml in RPMI 1640 
and incubated for 24 h at 37 "C in a humidified atmosphere 
to release unfixed IL-1. SN and cells were collected sepa- 
rately and stored at 4°C. 
2.5 Isolation of EC cytosol 
EC were treated with digitonin as described for human 
monocytes 1151. Digitonin treatment perforates the plasma 
membrane without affecting intracellular organelles, 
resulting in leakage of pure cytoplasm. Digitonin and its 
solvent ethanol were removed from the cytosol by ultra- 
filtration of PBS diluted samples using a YM membrane 
with a 10-kDa cutoff (Centricon-10, Amicon, Danvers, 
MA). After filter-sterilization, samples were stored at 
- 80°C. Lactate dehydrogenase (LDH) served as a marker 
for cytosol. Enzyme activity was determined by the rate of 
NAD' formation measured spectrophotometrically from 
the decrease in extinction at 340 nm. 
Immunoreactive IL-la, IL-lP and IL-6 were measured 
with commercially available specific ELISA kits (D. Berg- 
man, Eurogenetics, Tessenderlo, Belgium) using the pro- 
tocols provided by the manufacturers. TNF-a was deter- 
mined as described elsewhere 1211, with minor adaptations 
to enhance the sensitivity. Recombinant HuIL-la, IL-16, 
IL-6 and TNF-a served as positive controls. The amounts 
of cytokine were corrected for nonspecific binding of the 
culture medium, and expressed in pg per 106 viable cells. 
2.8 Depletion of CD45+ cells from EC suspensions 
Leukocytes were removed from freshly isolated PP EC by 
an immunomagnetic rosetting technique using the anti- 
CD45 mAb 2D1 (Becton Dickinson, Mountain View, CA) 
and goat-anti-mouse Ab-conjugated paramagnetic beads 
(Dynal, Oslo, Norway), as described 1221. Before and 
after depletion, the number of CD45' cells were deter- 
mined using a two-step immunoperoxidase technique on 
cytocentrifuge preparations. The percentage of CD45' 
cells was calculated by counting the number of cells show- 
ing positive staining from a total of 1000 cells. The deple- 
tion efficiency ranged from 95% to 99 YO. 
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Figure 1. Release of biologically active cytokines by PP and NN 
EC in basal medium. Levels of IL-1, IL-6 and TNF-a in 24 h SN 
of KBM cultures were measured using bioassays. Results are 
given in mean k SEM U/106 viable cells. PP: n = 29, 20 and 8; 
and NN: n = 32, 19 and 12 for IL-1, IL-6 and TNF-a, respectively. 
The p values indicate significant differences versus NN samples. 
Human PBMC isolated by Ficoll-Hypaque density gradient cen- 
trifugation and cultured for 24 h in RPMI 1640 supplemented with 
5 % human serum were used as a control. PBMC released 52 U 
IL-1; 24816 U IL-6; and 14 U TNF-a per lo6 cells. 
2.9 Statistical analysis 
Results were analyzed with the Wilcoxon Rank Sum Test 
using STATATM (Computing Resource Center, Los Ange- 
les, CA). Significant differences are indicated by p values. 
3 Results 
3.1 PP EC release increased amounts of biologically 
active IL-1 and IL-6, but not TNPa 
The amounts of cytokine released by EC from PP and NN 
skin are given in Fig. 1. It is evident that although NN EC 
release some IL-1, IL-6 and TNF-a under conditions ex 
vivo, PP EC release at least 15-fold more IL-1 (24 k 8 U/ 
10' EC, p < 0.0001) and 30-fold more IL-6 (61 k 40 U/106 
EC, p < 0.0001). However, PP EC did not release 
increased amounts of bioactive TNF-a. 
3.2 PP EC release biologically active IL-19 
The same samples were tested in the D10 assay using IL-1- 
neutralizing Ah as well as in IL-la and IL-1p ELISA. The 
effect of neutralizing Ah against IL-la and IL-1p on the 
IL-1 activity of EC SN is given in Fig. 2. When NN sam- 
ples were used, anti-IL-la Ah reduced the [3H]dThd 
incorporation to background levels, in contrast to anti-IL- 
1b Ab that did not affect the D10 proliferation (Fig. 2A). 
Thus, the IL-1 activity of NN samples is completely due to 
IL-la. The IL-1 activity of SN of PP EC, however, could 
only be completely blocked when both Ah were used 
simultaneously. The residual IL-1 activity of SN of PP EC 
neutralized with either Ah differed significantly from those 
of NN EC (p < 0.03 and p < 0.05 for neutralization of IL- 
la and IL-16 activity, respectively) (Fig. 2B). Approxi- 
mately 25 % of the IL-1 activity of SN of PP EC was due to 
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Figure 2. PP EC release biologically active IL-1p. Neutralization 
of IL-1 activity of 24 h ICBM SN of EC from PP and NN skin was 
determined with sheep-anti-rHuIL-la and/or IL-1p Ab using the 
D10 assay. Samples were diluted five times. Results are given in 
mean f SEM cpm (A). PP and NN groups consisted of 14 and 6 
patients, respectively. Controls: rHuIL-lp (12.5 U/ml): 
42 648 cpm; KBM: 6967 cpm; anti-IL-la Ab: 6874 cpm; anti-IL- 
l p  Ab: 5671 cpm; and both Ab: 4316 cpm. Results are also 
expressed as the residual IL-1 activity after neutralization (B), cal- 
culated as described in Sect. 2.6. Shown are mean f SEM. Condi- 
tioned medium of PBMC was used as a control. See legend to 
Fig. 1 for more details. Neutralization of PBMC SN with anti-IL- 
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Figure 3. Release of immunoreactive cytokines by PP and NN 
EC in basal medium. Levels of IL-la, IL-lp, IL-6 and TNF-a 
were measured using ELISA. Results are presented as mean f 
SEM p8/106 viable cells. PP: n = 19, 24, 12 and 8; and NN: 
n = 20, 19, 11 and 8 for IL-la, IL-lp, IL-6 and TNF-a, respec- 
tively. Conditioned medium of PBMC contained 151 pg IL-la; 
137 pg IL-1p; 70950 pg IL-6; and 677 pg TNF-a per lo6 cells. 
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Table 1. IL-1 activity of fixed PP and NN EC"' 
Psoriasis Normal p value 
control 
Directly fixed 0.9 f 0.9 1.3 f 1.3 NS 
Fixed after short-term 7.2 f 4.1 9.0.f 6.9 NS 
culture 
Unfixed control 41.3 f 19.5 4.5 ? 1.9 < 0.05 
a) Results are presented as mean f SEM U IL-l/lOh treated EC. 
Each experimental condition was performed with five to ten 
samples of both PP and NN EC. PBMC used as control cells 
expressed 0, 121 and 267 U IL-1/106 cells when directly fixed, 
fixed after short-term culture and unfixed, respectively. 
IL-10. SN of NN E C  contained negligible IL-1p activity. The 
use of anti-IL-6 Ab as a control had no effect in this system. 
The release of IL-10 by PP E C  was confirmed using IL- la  
and IL-lp ELISA. Fig. 3 shows that both E C  types released 
predominantly IL- la  under basal short-term culture condi- 
tions, with the amounts highest for PP E C  (134 k 45 versus 
37 k 12 pg/106 EC, p C0.009). The amounts of immuno- 
reactive IL-lb released by PP E C  were about three-fold 
lower than the corresponding amounts of IL- la  (40 f 14 pg/ 
10' EC), but nevertheless significantly increased when com- 
pared to the amounts of IL-1p released by NN E C  (p 
< 0.0001). These ELISA findings are in accordance with the 
IL-1 neutralization results, indicating that the increased 
basal release of bioactive IL-1 by PP E C  is due to both IL- la  
and IL-lp, which are released in a ratio of 3 : 1. ELISA 
results for IL-6 and TNF-a are also given in Fig. 3, and are 
in agreement with the data on IL-6 and TNF-a activity pre- 
sented in Fig. 1. Only levels of immunoreactive IL-6 in SN 
of PP E C  were significantly increased (p < 0.0007). 
3.3 PP EC do not express membrane IL-1 activity 
To study the interrelationship between the increased release 
of IL-1 and the previously observed membrane expression of 
IL-10 on PP E C  [ l l ] ,  the same E C  samples were tested for 
membrane IL-1 activity. E C  were fixed with glutaraldehyde 
and tested in the D10 assay. The possibility that the mea- 
sured IL-1 had leaked out of the fixed cells instead of repre- 
senting genuine membrane IL-1 activity was checked by tes- 
ting the SN of the fixed cells. These SN contained less than 
1 U per 10' cells. Results on IL-1 activity of fixed PP and NN 
EC samples are shown in Table 1. Fixation of freshly isolated 
PP and NN EC resulted in negligible IL-1 activities. Both 
types of E C  slightly upregulated the expression of IL-1 activ- 
ity during a 24 h culture in KBM. The levels of IL-1 activity 
found with unfixed PP E C  were significantly increased due 
to release of IL-1. 
3.4 PP EC express increased levels of cytosolic IL-lP 
To investigate the intracellular compartment, cell samples 
were treated with digitonin. The cytosolic fractions were 
0 ; 
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I I 
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Figure 4. PP EC express an increased cytosolic IL-lfi content. 
Levels of biologically active IL-1 (A) and immunoreactive IL-la 
and IL-1fi (B) in cytosolic fractions of freshly isolated EC and 
short-term cultured EC, termed ex vivo EC, from PP and NN skin 
are given in mean & SEM U or pg per 106 total cells, respetively. 
PP: n = 12 and 8; and NN: n = 6 and 6 for freshly isolated EC 
and EC ex vivo, respectively. Cytosolic fractions were obtained 
using digitonin. Samples were tested with the D10 assay, IL-la 
and IL-16 ELISA. The p values placed above bars of PP samples 
indicate significant differences between PP and the corresponding 
NN samples, whereas the p values placed above bars of NN sam- 
ples ex vivo indicate significant differences between NN samples 
ex vivo and freshly isolated NN samples. PP samples ex vivo did 
not differ significantly from freshly isolated PP samples. Freshly 
isolated PBMC and PBMC ex vivo expressed 0 U IL-1; 11 pg IL- 
l a ;  and 2 pg IL-lfi, and 109 U IL-1; 688 pg IL-la; and 1655 pg 
IL-1p intracellularly per total cells, respectively. 
tested in the DlO assay and in the IL- l a  and IL-1p ELISA in 
parallel. The efficiency of the ultrafiltration procedure was 
more than 95 YO as evaluated by the recovery of IL-1 from 
PBS spiked with 10 U IL-1. Fig. 4 A shows that the cytosolic 
IL-1 activity of freshly isolated PP and NN E C  was neglig- 
ible. Short-term culture resulted in an increase of intracellu- 
lar IL-1 activity in both EC types. However, this increase 
was only statistically significant for NN E C  (p <0.05). 
Levels of immunoreactive cytosolic IL- la  were significantly 
upregulated in NN E C  during a 24 h culture period 
(p < 0.02) (Fig. 4 B). The amounts of cytosolic IL-1p were 
negligible in NN EC. In freshly isolated PP EC,  the cytosolic 
IL- la  levels were somewhat higher than those of NN EC. 
The cytosolic IL-lp levels were significantly increased in 
freshly isolated (p < 0.002) and cultured PP E C  (p < 0.03) 
when compared to NN EC. However, intracellular IL- la  
and IL-1p levels did not significantly increase in PP E C  dur- 
ing short-term culture (Fig. 4B). 
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Figure 5.  PP E C  display enhanced cytosolic leakage. Loss of cel- 
lular viability during a 24 h culture of PP and NN E C  in KBM was 
measured by trypan blue exclusion (A). Given are mean k SEM 
percentage of trypan blue positive cells of freshly isolated E C  and 
EC ex vivo. PP: n = 11 and 8; and NN: n = 10 and 10 for freshly 
isolated EC and E C  ex vivo, respectively. Part of these samples, 
together with the corresponding conditioned media (termed SN 
ex vivo) were used to measure cytosolic and released LDH activity 
(B). Cytosolic fractions were obtained by digitonin treatment of 
the cells. The LDH activity is given in mean k SEM mU/lOh total 
cells. PP: n = 8, 5 and 8; and NN: n = 5 , s  and 10 for freshly isol- 
ated EC, EC ex vivo and SN ex vivo, respectively. PBMC did not 
show alterations in their viability using culture conditions as 
described in the legend to Fig. 1. LDH levels corresponding with 
freshly isolated PBMC, PBMC ex vivo and SN were 46, 100 and 
7 mU/lOh cells, respectively. 
3.5 PP EC show facilitated release of IL-1 due to 
enhanced cytosolic leakage 
Viabilities of freshly isolated EC from PP and NN skin, as 
determined by trypan blue dye exclusion, were similar. 
However, loss of viability during a 24 h culture in KBM was 
more than twofold higher for PP EC than for NN EC (p 
<0.0004), as shown in Fig. 5A. The loss of membrane 
integrity of PP EC correlated well with cytosolic leakage, 
monitored by release of LDH. The release of LDH from PP 
EC during a 24 h culture period was about twofold higher 
when compared to NN EC (Fig. 5 B, p c 0.007). This also 
applied to the concomitant decrease in cytosolic LDH. 
Release of cytosolic LDH correlated with that of IL-1. 
3.6 Production of IL-1 by PP EC is not due to 
contaminating intraepidermal CD4S cells 
Immunophenotyping of freshly isolated PP EC revealed 
that these cells contain about 5 % CD45' cells as well as 
Table 2. CD45- EC are the cellular source for IL-1 in psoriasis") 
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a) D10 proliferation rates of two separate CD45 depletion experi- 
ments are given in cpm (mean of triplicate values with SEM 
less than 5 %  of mean), corresponding to five times-diluted 
samples. The depletion efficiency in both experiments was 
more than 95 % . 
HLA-DR' cells [ 141. To determine whether intraepider- 
ma1 leukocytes were responsible for the PP EC-derived 
IL-1, CD45' cells were immunomagnetically depleted 
before measuring the IL-1 production. From Table 2 ,  it is 
evident that CD4.5' cells were not responsible for the 
enhanced production of biologically active IL-I. The pres- 
ence of IL-16 in the SN of CD45-depleted EC was con- 
firmed by neutralization studies as well as ELISA. 
4 Discussion 
In the present study, we show for the first time, using a 
large number of patients and controls, that PP EC release 
significantly increased amounts of bioactive IL-1. These 
results extend preliminary data reported by our group [17]. 
Other investigators, however, observed decreased epider- 
mal IL-1 bioactivity in psoriasis 16-81. The reported down- 
regulation of IL-la and up-regulation of a non-functional 
IL-16 in vivo [7] made us investigate the separate contribu- 
tions of IL-la and IL-1p to the observed extracellular IL-1 
activity. About 25 '30 of the IL-1 activity of PP samples was 
due to IL-10, while the IL-16 activity of NN samples was 
negligible. This corresponded nicely with the ELISA 
results. The capacity of PP EC to produce functionally 
active IL-lp is an unexpected and novel finding. Our 
observation that PP EC release equivalent amounts of 
bioactive and immunoreactive IL-1 does not point to the 
involvement of IL-1 receptor antagonist (IL-lra) in psoria- 
sis. 
Since overexpression of IL-16 in the membrane and the 
intracellular compartment of PP EC has previously been 
reported [lo, 111, we questioned whether PP EC express 
membrane-associated IL-1 activity. Membrane-associated 
IL-1 activity has been demonstrated on a variety of cell 
types, including keratinocytes [23]. Recently, it has been 
suggested that the assumed membrane IL-1 activity may 
be caused by the leakage of IL-1 from cells inadequately 
fixed with paraformaldehyde [24]. In our studies of rnem- 
brane IL-1 activity, glutaraldehyde-fixed EC were tested in 
the D10 assay. Glutaraldehyde proved to be a more strin- 
gent fixative than paraformaldehyde, and abrogated leak- 
age of intracellular IL-1. Our results do not provide evi- 
dence of a unique expression of membrane-bound IL-l by 
PP EC. 
Analysis of the intracellular compartment indicated that 
PP EC have a significantly increased cytosolic IL-10 con- 
tent, and that newly formed IL-la and IL-1p are not 
retained intracellularly under conditions ex vivo. The 
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opposite is true for NN EC, which express negligible levels 
of cytosolic IL-lp, accumulate IL-la synthesized de novo, 
but do not release it ex vivo (Figs. 3 and 4B). Antibodies 
directed against the mature IL-1 isoforms often underes- 
timate the actual intracellular pro-IL-1 levels due to 
incomplete cross-reactivity. This underlines the signifi- 
cance of the differences found at the cytosolic level with 
the IL-1 ELISA. Using freshly isolated EC, we could not 
confirm the decreased expression of cytosolic IL-la pro- 
tein in extracts from PP skin as reported by others [6, 71. 
Our findings of increased expression of intracellular IL-1p 
protein are in accordance with other reports [6, 7, 111. In 
line with our results is the recent report of increased 
expression of IL-16 mRNA in lesional as well as non- 
lesional psoriatic skin [25]. 
Loss of membrane integrity may be associated with pro- 
cessing and secretion of IL-1. In this respect, ionic per- 
turbation could be necessary for activation of the IL-1 con- 
verting enzyme [26]. The issue of whether membrane pro- 
cesses are involved in the production of biologically active 
IL-lp by PP EC was addressed. We demonstrated pro- 
found loss of membrane integrity and enhanced cytosolic 
leakage of PP EC under conditions ex vivo using trypan 
blue exclusion, FACScan analysis of propidium iodide- 
labeled cell samples (not shown), and measurement of 
LDH release. Thus, release of intracellularly stored prote- 
ins such as IL-1 is facilitated by cytosolic leakage in PP 
EC. For human monocytes, it has already been shown that 
the release of IL-1 paralleled that of LDH [27]. IL-lP pro- 
cessing may precede the secretion process, as previously 
suggested by Perregaux and others for monocytic cells 
[26]. Moreover, rapid apoptosis, as in macrophages that 
are targets for allospecific cytotoxic T cells, is also charac- 
terized by intracellular IL-16 processing [28]. The partial 
IL-1-neutralizing effect of anti-IL-1P Ab using cytosolic PP 
samples suggests that pro-IL-lP is processed intracellularly 
by PP EC. This is in accordance with the finding that intra- 
cellular levels of bioactive IL-1 correlate positively with 
the intracellular levels of immunoreactive IL-lP (not 
shown). In our laboratory, we are currently investigating 
to what extent necrosis and apoptosis contribute to the 
observed processing of cytosolic IL-lD. 
The enhanced IL-1 production by PP EC could be attri- 
buted to contaminating intraepidermal leukocytes. To 
identify the potential contribution of bone marrow-derived 
cells, we tested PBMC and a variety of cell lines such as a 
B cell line (JY), a T cell line (HSB) and a myelomonocytic 
cell line (HL-60) using serum-containing media with and 
without LPS as a stimulus (not shown). These experiments 
showed that PBMC, as expected, are a prominent source of 
IL-1 in all cellular compartments. Nevertheless, results of 
the depletion experiments indicate that CD4.Y EC were 
responsible for the observed IL-1 production ex vivo. 
These results were confirmed by testing normal human 
PBMC for their IL-1 levels under similar conditions ex 
vivo. Extracellular as well as intracellular IL-1 levels were 
not detectable when PBMC were cultured in the basal 
medium KBM at 104/ml and 105/ml, reflecting 1 % and 10 Yv 
potential leukocyte contamination of EC samples, respec- 
tively. Our results suggest the existence of an IL-1 conver- 
tase associated with resident PP EC, which up to now is 
thought to be confined to myelomonocytic cells. This could 
be in line with reports on enzyme alterations in PP EC [29]. 
Bioassay and ELISA findings showed that PP EC also 
released increased amounts of IL-6, but not TNF-a. Our 
IL-6 results are in agreement with findings based on skin 
biopsies [12] and blister fluids 1111, but in disagreement 
with findings based on extracts of the stratum corneum [8]. 
We found low, but consistent levels of biologically active 
and immunoreactive TNF-a in SN of both types of EC, 
while others could not detect TNF-a activity using extracts 
of the stratum corneum or blister fluids from either PP or 
NN skin [8, 131. Our findings may be attributable to the 
use of viable EC to investigate cytokine production levels. 
Cytokine production measured ex vivo is not merely based 
on the passive release of preformed cytosolic proteins (e .g .  
IL-l), and is, in our view, closely related to the cytokine 
production in vivo for the following reasons. First, up- 
regulation of cytosolic IL-1 proteins (Fig. 4, NN EC) and 
production of functionally active IL-lP during short-term 
culture (Fig. 2, PP EC) indicate active synthesis and pro- 
cessing of IL-1. Second, the release of increased amounts of 
IL-6, but not TNF-a, by PP EC point to selective cytokine 
synthesis de novo. Third, the reported up-regulation of 
cytosolic IL-lp by normal human keratinocytes in vitro [30] 
was not observed in our model, and the increased expres- 
sion of cytosolic IL-1p in PP EC is in agreement with 
reported findings in vivo (7, 251. Finally, treatment of pso- 
riatic lesions in vivo with a class I11 topical corticosteroid 
resulted in normalization of the amounts of IL-1 and IL-6 
released by PP EC under conditions ex vivo [17]. 
Taken together, these results provide clear evidence that 
PP EC show enhanced production of functionally active 
IL-la and IL-1p ex vivo due to enhanced release of IL-1 
and activation of cytosolic IL-lp concomitant with its 
release. PP EC also release increased levels of IL-6, but 
not TNF-a. Others have shown that normal human kerati- 
nocytes need a stimulus to produce substantial amounts of 
inflammatory cytokines in vitro [31]. Furthermore, 48 h 
serum-free culture SN of PP EC, but not NN EC, potenti- 
ate Tcell activation which was shown to be partly due to 
IL-1 [32]. The pathophysiological relevance of IL-1 in vivo 
is evidenced by transgenic mice in which EC-derived IL-1 
induced scaly inflammatory skin lesions with marked ery- 
thema, crusting and psoriasis-like histological features 
such as hyperkeratosis and a dense inflammatory infiltrate 
[33]. Mice which express an IL-6 transgene in basal kerati- 
nocytes demonstrated a thickened stratum corneum, but 
IL-6 did not exert direct proinflammatory actions and 
probably acts synergistically with EC-derived IL-1 [34]. 
We speculate that PP EC display an activated state in vivo 
and are easily triggered to express an enhanced production 
of IL-1 and IL-6. 
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